YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and Medtech companies successfully enter the Asian market, especially China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and transactions. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. We also represent leading Chinese pharma and biotech companies to explore licensing/partnership and acquisition opportunities globally.
Our core business is to help our clients understand the local regulatory and market environment, identify the best local strategic partners and advise them in licensing and financing deals to enter the Chinese/Japanese or overseas market successfully.
YAFO team consists of over 20 on the ground professionals with diverse Wall Street and healthcare industry background performing formulating strategy, execution, due diligence and communication work on behalf of our clients in China and Japan. Our professional team offers cross-cultural expertise while navigating entry into Asian markets and access to additional resources and funding.
Over the last decade, we have built strong relationships with the top 200+ pharma and Medtech companies in China, successfully helped many of our global clients to raise capital and license-out their products in the Chinese market.
• Host conferences and roadshows for foreign companies to meet Chinese investors
• Representing clients in China, attending conferences and trade shows to meet partners/investors
YAFO Capital is organizing 2020 ACCESS CHINA BD Forum at BIO International Convention 2020 on June 7, 2020 at the Omni Hotels & Resorts in San Diego. ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders to China, by directly meeting the right people for licensing and/or commercial partners. Our VIRTUAL ACCESS CHINA program offers forum participants opportunity to expand the exposure to much broader Chinese audiences.